vs
Side-by-side financial comparison of Invivyd, Inc. (IVVD) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $12.5M, roughly 1.4× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -64.3%, a 65.6% gap on every dollar of revenue. On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs -0.7%).
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
IVVD vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.2M | $12.5M |
| Net Profit | $-11.1M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -73.0% | 1.5% |
| Net Margin | -64.3% | 1.3% |
| Revenue YoY | 24.5% | -0.7% |
| Net Profit YoY | 40.0% | 129.2% |
| EPS (diluted) | $0.02 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.2M | $12.5M | ||
| Q3 25 | $13.1M | $14.6M | ||
| Q2 25 | $11.8M | $20.4M | ||
| Q1 25 | $11.3M | $14.6M | ||
| Q4 24 | $13.8M | $12.6M | ||
| Q3 24 | $9.3M | $16.9M | ||
| Q2 24 | $2.3M | $13.0M | ||
| Q1 24 | $0 | $9.9M |
| Q4 25 | $-11.1M | $163.0K | ||
| Q3 25 | $-10.5M | $-1.1M | ||
| Q2 25 | $-14.7M | $2.7M | ||
| Q1 25 | $-16.3M | $80.0K | ||
| Q4 24 | $-18.4M | $-559.0K | ||
| Q3 24 | $-60.7M | $3.0M | ||
| Q2 24 | $-47.2M | $856.0K | ||
| Q1 24 | $-43.5M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | -73.0% | 1.5% | ||
| Q3 25 | -84.0% | -5.4% | ||
| Q2 25 | -127.8% | 9.4% | ||
| Q1 25 | -149.7% | 1.8% | ||
| Q4 24 | -139.1% | -1.8% | ||
| Q3 24 | -670.0% | 19.0% | ||
| Q2 24 | -2175.2% | 8.0% | ||
| Q1 24 | — | 11.3% |
| Q4 25 | -64.3% | 1.3% | ||
| Q3 25 | -79.7% | -7.7% | ||
| Q2 25 | -124.4% | 13.1% | ||
| Q1 25 | -144.1% | 0.5% | ||
| Q4 24 | -133.5% | -4.4% | ||
| Q3 24 | -653.1% | 18.1% | ||
| Q2 24 | -2086.9% | 6.6% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | $0.02 | $0.00 | ||
| Q3 25 | $-0.06 | $-0.02 | ||
| Q2 25 | $-0.12 | $0.04 | ||
| Q1 25 | $-0.14 | $0.00 | ||
| Q4 24 | $-0.14 | $0.00 | ||
| Q3 24 | $-0.51 | $0.04 | ||
| Q2 24 | $-0.40 | $0.01 | ||
| Q1 24 | $-0.38 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.7M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $241.5M | $17.6M |
| Total Assets | $276.9M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.7M | $1.3M | ||
| Q3 25 | $85.0M | $429.0K | ||
| Q2 25 | $34.9M | $4.1M | ||
| Q1 25 | $48.1M | $1.8M | ||
| Q4 24 | $69.3M | $1.4M | ||
| Q3 24 | $106.9M | $2.9M | ||
| Q2 24 | $147.9M | $2.4M | ||
| Q1 24 | $189.4M | $2.0M |
| Q4 25 | $241.5M | $17.6M | ||
| Q3 25 | $93.1M | $17.2M | ||
| Q2 25 | $42.8M | $18.2M | ||
| Q1 25 | $54.1M | $15.2M | ||
| Q4 24 | $67.5M | $14.9M | ||
| Q3 24 | $83.2M | $15.2M | ||
| Q2 24 | $140.6M | $11.9M | ||
| Q1 24 | $178.5M | $5.0M |
| Q4 25 | $276.9M | $50.1M | ||
| Q3 25 | $139.2M | $54.0M | ||
| Q2 25 | $89.1M | $60.0M | ||
| Q1 25 | $103.7M | $57.0M | ||
| Q4 24 | $129.5M | $50.0M | ||
| Q3 24 | $161.9M | $48.0M | ||
| Q2 24 | $177.3M | $40.8M | ||
| Q1 24 | $215.5M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.5M | $1.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.5M | $1.8M | ||
| Q3 25 | $-8.3M | $-2.5M | ||
| Q2 25 | $-13.3M | $-654.0K | ||
| Q1 25 | $-21.1M | $-7.2M | ||
| Q4 24 | $-37.6M | $2.2M | ||
| Q3 24 | $-41.1M | $4.2M | ||
| Q2 24 | $-41.6M | $-565.0K | ||
| Q1 24 | $-50.2M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-13.3M | — | ||
| Q1 25 | $-21.3M | — | ||
| Q4 24 | $-37.6M | $-404.0K | ||
| Q3 24 | $-41.1M | $2.8M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | $-50.4M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -112.9% | — | ||
| Q1 25 | -188.2% | — | ||
| Q4 24 | -272.2% | -3.2% | ||
| Q3 24 | -441.6% | 16.6% | ||
| Q2 24 | — | -8.0% | ||
| Q1 24 | — | -39.9% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.0% | 20.6% | ||
| Q3 24 | 0.1% | 8.3% | ||
| Q2 24 | 0.0% | 3.7% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
